Title : Phenotypic and molecular biological analysis of human butyrylcholinesterase variants - La Du_1990_Clin.Biochem_23_423 |
Author(s) : La Du BN , Bartels CF , Nogueira CP , Hajra A , Lightstone H , van der Spek AF , Lockridge O |
Ref : Clinical Biochemistry , 23 :423 , 1990 |
Abstract :
Our laboratory has recently shown that several variant forms of human butyrylcholinesterase, associated with unusual sensitivity to succinylcholine, are caused by specific mutations within the structural DNA coding for this enzyme. Atypical (dibucaine-resistant) butyrylcholinesterase is caused by a point mutation at nucleotide position 209(GAT-- greater than GGT), which changes aspartate 70 to glycine. One fluoride-resistant variant family has a point mutation at nucleotide 728(ACG-- greater than ATG), which changes threonine 243 to methionine. Another type of fluoride-resistant variant has a point mutation at nucleotide 1169(GGT-- greater than GTT), which changes glycine 390 to valine. One type of silent phenotype is due to a frame-shift mutation at nucleotide position 351(GGT-- greater than GGAG). A polymorphic site at nucleotide position 1615 (GCA/ACA), coding for Ala/Thr, accounts for the quantitative K-variant, which causes an approximate one-third reduction of activity, if Thr occupies that position at codon 539. Examples are given to illustrate the advantages of using a combination of the new DNA analytical techniques, including: the use of allele-specific probes, with the standard serum cholinesterase phenotyping methods. More accurate typing of patients with certain variants is now possible; pedigree analysis will be aided by the improved methodology. |
PubMedSearch : La Du_1990_Clin.Biochem_23_423 |
PubMedID: 2253336 |
La Du BN, Bartels CF, Nogueira CP, Hajra A, Lightstone H, van der Spek AF, Lockridge O (1990)
Phenotypic and molecular biological analysis of human butyrylcholinesterase variants
Clinical Biochemistry
23 :423
La Du BN, Bartels CF, Nogueira CP, Hajra A, Lightstone H, van der Spek AF, Lockridge O (1990)
Clinical Biochemistry
23 :423